open access

Vol 9, No 5 (2013)
Review paper
Published online: 2013-12-03
Get Citation

Enzalutamide — a new agent for treatment of castration-resistant prostate cancer

Piotr J. Wysocki
Onkol. Prak. Klin 2013;9(5):186-190.

open access

Vol 9, No 5 (2013)
REVIEW ARTICLES
Published online: 2013-12-03

Abstract

Systemic treatment of prostate cancer is primarily based on androgen deprivation (surgical/pharmacological castration) which reflects hormone-dependent biology of this malignancy. Despite significant activity of hormonal therapy in advanced prostate cancer, the progression of disease in the majority of castrated patients is inevitable.This phenomenon results from development of intrinsic mechanisms of resistance to systemic androgen deprivation. Elucidation of the molecular mechanisms of resistance has paved way toward development of novel, targeted hormonal agents. Two years ago, abiraterone acetate was approved in EU for treatment of castration-resistant prostate cancer following docetaxel. In 2013, EMEA approved a second drug — enzalutamide (an extremely strong antiandrogen) for second-line treatment of CRPC. Both drugs — enzalutamide and abiraterone acetate have significantly improved prognosis of advanced CRPC patients.

Abstract

Systemic treatment of prostate cancer is primarily based on androgen deprivation (surgical/pharmacological castration) which reflects hormone-dependent biology of this malignancy. Despite significant activity of hormonal therapy in advanced prostate cancer, the progression of disease in the majority of castrated patients is inevitable.This phenomenon results from development of intrinsic mechanisms of resistance to systemic androgen deprivation. Elucidation of the molecular mechanisms of resistance has paved way toward development of novel, targeted hormonal agents. Two years ago, abiraterone acetate was approved in EU for treatment of castration-resistant prostate cancer following docetaxel. In 2013, EMEA approved a second drug — enzalutamide (an extremely strong antiandrogen) for second-line treatment of CRPC. Both drugs — enzalutamide and abiraterone acetate have significantly improved prognosis of advanced CRPC patients.
Get Citation

Keywords

enzalutamide, prostate cancer, androgen receptor, castration

About this article
Title

Enzalutamide — a new agent for treatment of castration-resistant prostate cancer

Journal

Oncology in Clinical Practice

Issue

Vol 9, No 5 (2013)

Article type

Review paper

Pages

186-190

Published online

2013-12-03

Bibliographic record

Onkol. Prak. Klin 2013;9(5):186-190.

Keywords

enzalutamide
prostate cancer
androgen receptor
castration

Authors

Piotr J. Wysocki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl